LoriJWirthMD

Oncology • Boston, MA

Assistant Professor of Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Wirth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wirth's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-724-4000

Fax+1 617-726-0453
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997

Certifications & Licensure

ME State Medical License 2021 - 2026
MA State Medical License 2000 - 2025
NH State Medical License 2013 - 2025
RI State Medical License 2021 - 2024
NY State Medical License 1998 - 2000
American Board of Internal Medicine Medical Oncology

Clinical Trials

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Start of enrollment: 2002 Jun 01
Completed
Phase 2
Capecitabine For Nasopharyngeal Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Start of enrollment: 1999 Jan 01
Completed
Phase 2
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck Start of enrollment: 2006 Apr 01
Completed
Phase 1
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer Start of enrollment: 2010 Dec 01
Completed
Phase 2
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer Start of enrollment: 2011 Nov 01
Completed
Phase 1
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Start of enrollment: 2012 Nov 07
Active, not recruiting
Phase 2
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Start of enrollment: 2013 May 08
Completed
Phase 2
2 Phase Use Of Educational Materials In Head And Neck Cancer Center Start of enrollment: 2014 Aug 12
Completed
Not Applicable
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Start of enrollment: 2018 Feb 07
Completed
Phase 2
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2017 Apr 25
Completed
Phase 2
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Start of enrollment: 2023 Mar 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
Daniel A Ruiz-Torres, Sophia Z Shalhout, Saskia Naegele, Archana Podury, Lori Wirth, Daniel L Faden> ;Oral Oncology. 2024 Apr 1
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, Matthew H Taylor, Martin Schuler, Viola W Zhu, Julien Hadoux, Giuseppe Curigliano, Lori Wirth, Justin F Gainor, Guzman Alo...> ;Thyroid. 2024 Jan 1
2 citations
Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced T...
Amanda Silver Karcioglu, Amr H Abdelhamid Ahmed, Zipei Feng, Marika Russell, David C Shonka Jr, Ayaka Iwata, Maria Cabanillas, Jennifer J Shin, Natalia Kyriazidis, Jon...> ;Thyroid. 2023 Oct 1
2 citations
Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.
Matti L Gild, Martyn Bullock, Venessa Tsang, Roderick J Clifton-Bligh, Bruce G Robinson, Lori J Wirth> ;Thyroid. 2023 Jun 1
Amygdalar activity measured using FDG-PET/CT at head and neck cancer staging independently predicts survival.
Malek Z O Hassan, Ahmed Tawakol, Ying Wang, Raza M Alvi, Magid Awadalla, Maeve Jones-O'Connor, Rula B Bakar, Dahlia Banerji, Adam Rokicki, Lili Zhang, Connor P Mulliga...> ;Plos One. 2023 Jan 1
9 citations
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
David G Pfister, Robert I Haddad, Francis P Worden, Jared Weiss, Ranee Mehra, Laura Q M Chow, Stephen V Liu, Hyunseok Kang, Nabil F Saba, Lori J Wirth, Ammar Sukari, E...> ;Cancer Medicine. 2023 Mar 1
2 citations
Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance.
Maoxuan Lin, Moshe Sade-Feldman, Lori Wirth, Michael S Lawrence, Daniel L Faden> ;NPJ Precision Oncology. 2022 Oct 10
13 citations
Accelerated approvals hit the target in precision oncology.
Vivek Subbiah, Lori J Wirth, Razelle Kurzrock, Richard Pazdur, Julia A Beaver, Harpreet Singh, Gautam U Mehta> ;Nature Medicine. 2022 Oct 1
3 citations
Case Report ofFusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma.
Hannah Lee, Vimal Krishnan, Lori J Wirth, Carmelo Nucera, Mariza Venturina, Peter M Sadow, Alain Mita, Wendy Sacks> ;Thyroid. 2022 Dec 1
12 citations
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve-mutant medullary thyroid cancer.
Lori J Wirth, Marcia S Brose, Rossella Elisei, Jaume Capdevila, Ana O Hoff, Mimi I Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Meng Xia, Patricia Maeda, Eric Sherman> ;Future Oncology. 2022 Sep 1
89 citations
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Robert I Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitne...> ;Journal of the National Comprehensive Cancer Network. 2022 Aug 1
1 citations
The Prediction of Cardiac Events Using Contemporary Risk Prediction Models after Radiation Therapy for Head and Neck Cancer.
Raza M Alvi, Thiago Quinaglia, Aferdita Spahillari, Giselle A Suero-Abreu, Malek Z O Hassan, Carlos Gongora, Hannah K Gilman, Sofia Nikolaidou, Supraja Sama, Lori J Wi...> ;Cancers. 2022 Jul 27
4 citations
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.
Dora Dias-Santagata, Rebecca S Heist, Adam Z Bard, Annacarolina F L da Silva, Ibiayi Dagogo-Jack, Valentina Nardi, Lauren L Ritterhouse, Laura M Spring, Nicholas Jesso...> ;The Oncologist. 2022 Nov 3
4 citations
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Lori J Wirth, Cosimo Durante, Duncan J Topliss, Eric Winquist, Eyal Robenshtok, Hiroyuki Iwasaki, Markus Luster, Rossella Elisei, Sophie Leboulleux, Makoto Tahara> ;The Oncologist. 2022 Jul 5
14 citations
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
Or Kalchiem-Dekel, Christina J Falcon, Christine M Bestvina, Dazhi Liu, Lauren A Kaplanis, Clare Wilhelm, Jordan Eichholz, Guilherme Harada, Lori J Wirth, Subba R Digu...> ;Journal of Thoracic Oncology. 2022 Sep 1
7 citations
Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global ...
Naomi Kiyota, Makoto Tahara, Bruce Robinson, Martin Schlumberger, Steven I Sherman, Sophie Leboulleux, Eun Kyung Lee, Takuya Suzuki, Min Ren, Kazuma Fushimi, Lori J Wirth> ;Cancer. 2022 Jun 15
18 citations
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
Alan L Ho, Marek Dedecjus, Lori J Wirth, R Michael Tuttle, William B Inabnet 3rd, Jan Tennvall, Fernanda Vaisman, Lars Bastholt, Andrew G Gianoukakis, Patrice Rodien, ...> ;Journal of Clinical Oncology. 2022 Jun 10
18 citations
Dabrafenib Versus Dabrafenib + Trametinib in-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicen...
Naifa L Busaidy, Bhavana Konda, Lai Wei, Lori J Wirth, Catherine Devine, Gregory A Daniels, Jonas A DeSouza, Ming Poi, Nathan D Seligson, Maria E Cabanillas, Jennifer ...> ;Thyroid. 2022 Oct 1
30 citations
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining...
David C Shonka Jr, Alan Ho, Ashish V Chintakuntlawar, Jessica L Geiger, Jong C Park, Nagashree Seetharamu, Sina Jasim, Amr H Abdelhamid Ahmed, Keith C Bible, Marcia S ...> ;Head & Neck. 2022 Jun 1
31 citations
Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.
Connor J O'Boyle, Giulia Siravegna, Shohreh Varmeh, Natalia Queenan, Alexa Michel, Kim Chang Sing Pang, Jarrod Stein, Julia C Thierauf, Peter M Sadow, William C Faquin...> ;Cancer. 2022 Jun 1
Phase II Study of Cabozantinib in Patients With Bone Metastasis.
Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori Wirth, Justin F Gainor, Alona Muzikansky, Lecia V Sequist, Ryan J Sullivan, Panagiotis M Fidias, Alice Shaw, Rebecc...> ;The Oncologist. 2022 Jul 5
36 citations
Cell free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.
Giulia Siravegna, Connor J O'Boyle, Shohreh Varmeh, Natalia Queenan, Alexa G. Michel, Jarrod Stein, Julia Thierauf, Peter M. Sadow, William C. Faquin, Simon K Perry, A...> ;Clinical Cancer Research. 2021 Dec 2
5 citations
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce G. Robinson, Lori J. Wirth, Lisa M. Hess, Min Hua Jen, Jennifer Kherani, Elizabeth...> ;The Oncologist. 2021 Sep 30
7 citations
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Lori J. Wirth, Bruce G. Robinson, Valentina Boni, Daniel Shao-Weng Tan, Caroline E. McCoach, Erminia Massarelli, Lisa M. Hess, Min Hua Jen, Jennifer Kherani, Elizabeth...> ;The Oncologist. 2021 Sep 30
7 citations
Screening and Validation of Molecular Targeted Radiosensitizers.
Henning Willers, Xiao Pan, Nathalie Borgeaud, Irina Korovina, Lydia Koi, Regina K. Egan, Patricia Greninger, Aliza Rosenkranz, J. H. Kung, Andrew S. Liss, Leslie A. Pa...> ;International Journal of Radiation Oncology, Biology, Physics. 2021 Jul 31
Join now to see all

Journal Articles

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Still Perfecting Radioiodine in Thyroid Cancer, After All These Years
Lori Wirth, MD, The Journal of Clinical Endocrinology and Metabolism
Selective RET Kinase Inhibition for Patients with RET-Altered Cancers
L J Wirth, N L Busaidy, M E Cabanillas, Annals of Oncology

Lectures

Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refr...
2019 ASCO Annual Meeting - 6/1/2019
Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and potential impact on systemic therapy.
2019 ASCO Annual Meeting - 6/1/2019
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020

Press Mentions

How Boston Is Beating CancerJanuary 24th, 2023
The Beginning of the American Thyroid Association Centennial YearJanuary 1st, 2023
Massachusetts Hospital Treats 11-Year-Old from Bangladesh for Rare Eye CancerFebruary 18th, 2022
Join now to see all

Hospital Affiliations

Salem HospitalSalem, Massachusetts
Massachusetts General HospitalBoston, Massachusetts
Massachusetts Eye and EarBoston, Massachusetts